EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001
December 04, 2023 04:00 ET
|
AKAMPION
Presentation at the World Vaccine Congress West Coast2023EBV-001 is designed for the prevention of Epstein-Barr Virus (EBV)-induced diseases via high titers of potent, neutralizing antibodiesNovel...
Ebenbuild erhält öffentliche Förderung im Rahmen des UBIC-Konsortiums für das Projekt "Digital Lung Twin“
November 28, 2023 04:00 ET
|
AKAMPION
Bundesministerium für Bildung und Forschung (BMBF) bewilligt Fördermittel in Höhe von bis zu 1,8 Millionen Euro München, Deutschland, 28. November 2023 -- Ebenbuild, ein Unternehmen, das...
Ebenbuild to Receive Public Funding Under UBIC Consortium for Digital Lung Twin Project
November 28, 2023 04:00 ET
|
AKAMPION
Funding up to Euro 1.8 million awarded by German Federal Ministry of Education and Research BMBF Munich, Germany, November 28, 2023 -- Ebenbuild, a company developing personalized, AI-driven...
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
November 20, 2023 04:00 ET
|
AKAMPION
- Phase I data show safety and tolerability at clinically significant dose levels- New class of anti-infectives to treat infections with Gram-negative bacteria JERUSALEM, Israel, November 20,...
Dr. Hartmut Tintrup joins Cellbox Solutions GmbH as new CEO
November 01, 2023 05:00 ET
|
AKAMPION
- Seasoned business development professional joins from Lonza PRESS RELEASE. Cologne, Germany — November 1, 2023 - Cellbox Solutions GmbH, a leading provider of live cell logistics solutions for...
BellaSeno Presents Novel Production Workflow for Customized, 3D-Printed Bone Scaffolds
October 30, 2023 05:00 ET
|
AKAMPION
Presentation at the German Congress of Orthopaedics and Traumatology (DKOU)Treatment of large segmental bone defects with resorbable scaffoldsLeading-edge workflow for the design and manufacturing of...
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
October 24, 2023 04:00 ET
|
AKAMPION
Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress...
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
October 17, 2023 04:00 ET
|
AKAMPION
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors ...
Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
September 26, 2023 04:00 ET
|
AKAMPION
- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected in Q1/ 2024 with study completion planned...
Cellbox Solutions Submits Device Master File (DMF) to the U.S. FDA
September 25, 2023 04:00 ET
|
AKAMPION
Submission represents an important step towards establishing the Cellbox Live Shipment Technology as a new standard for warm chain logistic in the cell therapy sectorCellbox customers can now...